12.01
price up icon0.08%   0.010
pre-market  Vorhandelsmarkt:  11.60   -0.41   -3.41%
loading
Schlusskurs vom Vortag:
$12.00
Offen:
$11.9
24-Stunden-Volumen:
478.59K
Relative Volume:
0.91
Marktkapitalisierung:
$594.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.2547
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+0.50%
1M Leistung:
+1.01%
6M Leistung:
-2.52%
1J Leistung:
+3.80%
1-Tages-Spanne:
Value
$11.77
$12.82
1-Wochen-Bereich:
Value
$11.42
$12.82
52-Wochen-Spanne:
Value
$7.30
$15.50

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Firmenname
Kalvista Pharmaceuticals Inc
Name
Telefon
(857) 999-0075
Name
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Mitarbeiter
0
Name
Twitter
@kalvista
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
KALV's Discussions on Twitter

Vergleichen Sie KALV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
12.01 594.10M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Eingeleitet JMP Securities Mkt Outperform
2025-01-07 Eingeleitet TD Cowen Buy
2024-12-18 Eingeleitet BofA Securities Buy
2020-06-15 Eingeleitet H.C. Wainwright Buy
2019-07-29 Eingeleitet SVB Leerink Outperform
2019-03-20 Eingeleitet Needham Buy
2018-10-30 Eingeleitet Jefferies Buy
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2017-08-31 Eingeleitet BTIG Research Buy
Alle ansehen

Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten

pulisher
03:43 AM

Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

03:43 AM
pulisher
Apr 19, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com

Apr 18, 2025
pulisher
Apr 17, 2025

(KALV) Trading Report - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle

Apr 13, 2025
pulisher
Apr 13, 2025

The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter

Apr 13, 2025
pulisher
Apr 12, 2025

KalVista: Poised For Rare Disease Transformation - Seeking Alpha

Apr 12, 2025
pulisher
Apr 10, 2025

Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News

Apr 10, 2025
pulisher
Apr 09, 2025

KalVista licensing deal with Kaken - The Pharma Letter

Apr 09, 2025
pulisher
Apr 09, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo

Apr 08, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT) - The Globe and Mail

Apr 08, 2025
pulisher
Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com

Apr 04, 2025
pulisher
Apr 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace

Apr 03, 2025
pulisher
Apr 01, 2025

Where are the Opportunities in (KALV) - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Mar 31, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025
pulisher
Mar 31, 2025

Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Q4 Earnings Estimate for KALV Issued By Leerink Partnrs - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - MarketScreener

Mar 25, 2025

Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):